Uncover groundbreaking insights into cancer DNA changes with the new BACDAC tool, developed by Mayo Clinic. This innovative tool identifies hidden genomic alterations,even in low-quality samples,offering a crucial step forward in cancer research. BACDAC analyzes the entire genome, predicting tumor behavior and paving the way for more personalized treatment decisions. The ability to detect chromosome instability and whole-genome doubling, a key indicator of aggressive tumor growth, is a substantial advancement. news Directory 3 reports on the tool’s ability to provide clinicians with a clearer picture of a tumor’s structural changes. What does the future hold for cancer diagnosis and treatment planning? Discover what’s next …
Updated June 22, 2025
A new computational tool developed by Mayo Clinic researchers is designed to detect tough-to-find genetic changes in cancer cells. These structural alterations within a tumor’s DNA can promote aggressive growth and resist standard testing, particularly when tissue samples are limited or degraded.
The tool, called BACDAC, illuminates these previously obscured genomic patterns. It uses DNA sequencing to analyze the entire genome, even in samples with low purity or coverage, to identify signs of genomic instability. Researchers believe BACDAC can help clinicians better predict tumor behavior and personalize treatment strategies.
Detecting Chromosome Instability
BACDAC focuses on ploidy, the number of complete chromosome sets in a cell. Healthy human cells have two sets (46 chromosomes), but cancer cells often exhibit gains or losses, disrupting this balance and fostering uncontrolled growth.
In a study published in Genome Biology, the research team used BACDAC to analyze over 650 tumors across 12 cancer types. The tool detected instances of whole-genome doubling,where a tumor duplicates its entire DNA. This ploidy abnormality is often associated with aggressive cancer behavior and treatment resistance.
“This tool lets us see a layer of the genome that’s been invisible until now,” said Dr.George Vasmatzis, a lead author of the study and co-director of Mayo Clinic’s Biomarker Discovery Program. “We’ve spent decades studying the biology of genomic instability. This is the first time we’ve been able to translate that knowledge into a tool that works at scale.”
BACDAC also generates a visual summary of a tumor’s genomic landscape. The Constellation Plot provides an intuitive view of chromosome stability, aiding researchers and pathologists in interpreting results.
The Mayo Clinic team plans to validate BACDAC further and develop it into a clinically deployable diagnostic tool, potentially informing treatment decisions by providing a clearer picture of a tumor’s structural changes.
What’s next
Future research will focus on integrating BACDAC into clinical workflows to improve cancer diagnosis and treatment planning.
